Palabras clave
dengue
dengue grave
extravasación
hemorragias
tratamiento
dengue grave
extravasación
hemorragias
tratamiento
Cómo citar
1.
SATI C de infectología crítica. Dengue grave. Rev Arg de Ter Int. [Internet]. 2 de febrero de 2021 [citado 24 de abril de 2024];38:e707.10102020. Disponible en: https://revista.sati.org.ar/index.php/MI/article/view/707
Resumen
El dengue es la arbovirosis de mayor incidencia a nivel mundial, incluyendo América y especialmente Argentina. Es un Flavivirus, con 4 serotipos y cuyo vector es el Aedes aegypti, mosquito con hábitos domiciliarios y peri domiciliarios. En el 2009 se clasifica en: dengue sin signos de alarma, dengue con signo de alarma y dengue grave, siendo este último de gran importancia para el medico intensivista. La extravasación de plasma, hemorragias y compromiso de órganos son los puntos clave en el diagnóstico y son los pilares del tratamiento del dengue grave. El Comité de Infectología Critica de Terapia intensiva, realizo una exhaustiva revisión de epidemiologia, diagnóstico, clínica, tratamiento, prevención del dengue grave, con un enfoque para los profesionales de terapia intensiva
Citas
1. Enfermedades infecciosas | dengue GUIA PARA EL EQUIPO DE SALUD. Ministerio de Salud de la Nación. 4ª edición ,2015
2. PAHO: warns of the complex situation of dengue in Latin America and the Caribbean
3. OPS/OMS. Actualización Epidemiológica: Dengue. 7 de febrero de 2020
4. Boletín integrado de vigilancia N0492 Ministerio de Salud de Nación
5. Instructivo de Toma de Muestra para derivación: http://www.anlis.gov.ar/inevh/.
6. Organización Mundial de la Salud. Fiebre hemorrágica del dengue: diagnóstico, tratamiento, prevención y control, 2ª edición. OMS, Ginebra 1997
7. World Health Organization. Dengue guidelines for diagnosis, treatment, prevention, and control. Geneva: SEAMEO Regional Tropical Medicine and Public Health Network; 2009.
8. Dengue: guías para la atención de enfermos en la Región de las Américas. 2.ed. Washington, DC: OPS, 2016.
9. Saiful Safuan Md-Sani, Julina Md-Noor, Winn-Hui Han, Syang-Pyang Gan, Nor-Salina Rani, Hui-Loo Tan, et al. Prediction of mortality in severe dengue cases BMC Infectious Diseases (2018) 18:232 doi: 10.1186/s12879-018-3141-6
10. Yacoub S, Wertheim H, Simmons CP, Screaton G, Wills B. Cardiovascular manifestations of the emerging dengue pandemic. Nat Rev Cardiol. 2014;11(6):335–345. doi: 10.1038 / nrcardio.2014.40.
11. Rigau-Perez JG, Clark GG, Gubler DJ, Reiter P, Sanders E, Vorndam AV. Dengue and dengue haemorrhagic fever. Lancet. 1998;352(9132):971–977. doi: 10.1016 / s0140-6736 (97) 12483-7.
12. World Health Organization. Handbook for clinical management of dengue. Geneva: World Health Organization; 2012
13. Dung NM, Day NP, Tam DT, Loan HT, Chau HT, Minh LN ,et al. Fluid replacement in dengue shock syndrome: a randomized, double-blind comparison of four intravenous-fluid regimens. Clin Infect Dis. 1999;29(4):787–794 doi: 10.1086 / 520435.
14. Ngo NT, Cao XT, Kneen R, Wills B, Nguyen V , Nguyen T, et al. Acute management of dengue shock syndrome: a randomized double-blind comparison of 4 intravenous fluid regimens in the first hour. Clin Infect Dis. 2001;32(2):204–213 doi 10.1086 / 318479
15. Lee IK, Lee WH, Yang KD, Liu J. Comparison of the effects of oral hydration and intravenous fluid replacement in adult patients with non-shock dengue hemorrhagic fever in Taiwan. Trans R Soc Trop Med Hyg. 2010;104(8):541–545 doi: 10.1016 / j.trstmh.2010.05.003
16. Lee TH, Wong JG, Leo YS, Thein T, Ng E, Lee E, et al. Potential harm of prophylactic platelet transfusion in adult dengue patients. PLoS Negl Trop Dis. 2016;10(3): e0004576 doi: 10.1371 / journal.pntd.0004576.
17. Sharma A, Charles K, Chadee D, Teelucksingh S. Dengue hemorrhagic fever in Trinidad and Tobago: a case for a conservative approach to platelet transfusion. Am J Trop Med Hyg. 2012;86(3):531–535 doi: 10.4269/ajtmh.2012.10-0209
18. The T, Thu T, Minh D, Van N, Tinh H, Vinh C, et al. Clinical features of dengue in a large Vietnamese cohort: intrinsically lower platelet counts and greater risk for bleeding in adults than children. PLoS Negl Trop Dis. 2012;6(6):1679. doi: 10.1371/journal.pntd.0001679
19. Salgado DM, Eltit JM, Mansfield K, Panqueba C, Castro D, Roció Vega R, et al. Heart and skeletal muscle are targets of dengue virus infection. Pediatr Infect Dis J. 2010;29 (3):238–242 doi: 10.1097/INF.0b013e3181bc3c5b
20. Sahu R, Verma R, Jain A, Garg R, Singh M, Malhotra H, et al. Neurologic complications in dengue virus infection: a prospective cohort study. Neurology. 2014;83 (18):1601–16 doi: 10.1212 / WNL.0000000000000935.
21. Carod-Artal FJ, Wichmann O, Farrar J, Gascón J. Neurological complications of dengue virus infection. Lancet Neurol. 2013;12(9):906–91948 doi: 10.1016 / S1474-4422 (13) 70150-9
22. Kuo MC, Lu PL, Chang JM, Lin MY,* Tsai JJ, Chen YH, et al. Impact of renal failure on the outcome of dengue viral infection. Clin J Am Soc Nephrol. 2008;3 (5):1350–1356 doi: 10.2215/CJN.00020108
23. Oliveira JF, Burdmann EA. Dengue-associated acute kidney injury. Clin Kidney J. 2015;8(6):681–685. doi: 10.1093/ckj/sfv106
24. Laoprasopwattana K, Pruekprasert P, Dissaneewate P, Geater A, Vachvanichsanong P. Outcome of dengue hemorrhagic fever-caused acute kidney injury in Thai children. J Pediatr. 2010;157(2):303–309. DOI: 10.1016 / j.jpeds.2010.02.008
25. Tan LH, Lum LC, Omar SF, Kan FK. Hemophagocytosis in dengue: comprehensive report of six cases. J Clin Virol. 2012;55(1):79– 82. doi: 10.1016 / j.jcv.2012.06.005
26. Thein TL, Ng EL, Yeang MS, Leo YS, Lye DC. Risk factors for concurrent bacteremia in adult patients with dengue. J Microbiol Immunol Infect. 2015. doi:10.1016/j.jmii.2015.06.008
27. Castro JE, Vado-Solis I, Perez-Osorio C, Fredeking. TM. Modulation of cytokine and cytokine receptor/antagonist by treatment with doxycycline and tetracycline in patients with dengue fever. Clin Dev Immunol. 2011; 2011:370872 doi: 10.1155 / 2011/370872
28. Global strategy for Dengue prevention and control 2012-2020.WHO Library 2012. ISBN 978 92 4 150403 4
2. PAHO: warns of the complex situation of dengue in Latin America and the Caribbean
3. OPS/OMS. Actualización Epidemiológica: Dengue. 7 de febrero de 2020
4. Boletín integrado de vigilancia N0492 Ministerio de Salud de Nación
5. Instructivo de Toma de Muestra para derivación: http://www.anlis.gov.ar/inevh/.
6. Organización Mundial de la Salud. Fiebre hemorrágica del dengue: diagnóstico, tratamiento, prevención y control, 2ª edición. OMS, Ginebra 1997
7. World Health Organization. Dengue guidelines for diagnosis, treatment, prevention, and control. Geneva: SEAMEO Regional Tropical Medicine and Public Health Network; 2009.
8. Dengue: guías para la atención de enfermos en la Región de las Américas. 2.ed. Washington, DC: OPS, 2016.
9. Saiful Safuan Md-Sani, Julina Md-Noor, Winn-Hui Han, Syang-Pyang Gan, Nor-Salina Rani, Hui-Loo Tan, et al. Prediction of mortality in severe dengue cases BMC Infectious Diseases (2018) 18:232 doi: 10.1186/s12879-018-3141-6
10. Yacoub S, Wertheim H, Simmons CP, Screaton G, Wills B. Cardiovascular manifestations of the emerging dengue pandemic. Nat Rev Cardiol. 2014;11(6):335–345. doi: 10.1038 / nrcardio.2014.40.
11. Rigau-Perez JG, Clark GG, Gubler DJ, Reiter P, Sanders E, Vorndam AV. Dengue and dengue haemorrhagic fever. Lancet. 1998;352(9132):971–977. doi: 10.1016 / s0140-6736 (97) 12483-7.
12. World Health Organization. Handbook for clinical management of dengue. Geneva: World Health Organization; 2012
13. Dung NM, Day NP, Tam DT, Loan HT, Chau HT, Minh LN ,et al. Fluid replacement in dengue shock syndrome: a randomized, double-blind comparison of four intravenous-fluid regimens. Clin Infect Dis. 1999;29(4):787–794 doi: 10.1086 / 520435.
14. Ngo NT, Cao XT, Kneen R, Wills B, Nguyen V , Nguyen T, et al. Acute management of dengue shock syndrome: a randomized double-blind comparison of 4 intravenous fluid regimens in the first hour. Clin Infect Dis. 2001;32(2):204–213 doi 10.1086 / 318479
15. Lee IK, Lee WH, Yang KD, Liu J. Comparison of the effects of oral hydration and intravenous fluid replacement in adult patients with non-shock dengue hemorrhagic fever in Taiwan. Trans R Soc Trop Med Hyg. 2010;104(8):541–545 doi: 10.1016 / j.trstmh.2010.05.003
16. Lee TH, Wong JG, Leo YS, Thein T, Ng E, Lee E, et al. Potential harm of prophylactic platelet transfusion in adult dengue patients. PLoS Negl Trop Dis. 2016;10(3): e0004576 doi: 10.1371 / journal.pntd.0004576.
17. Sharma A, Charles K, Chadee D, Teelucksingh S. Dengue hemorrhagic fever in Trinidad and Tobago: a case for a conservative approach to platelet transfusion. Am J Trop Med Hyg. 2012;86(3):531–535 doi: 10.4269/ajtmh.2012.10-0209
18. The T, Thu T, Minh D, Van N, Tinh H, Vinh C, et al. Clinical features of dengue in a large Vietnamese cohort: intrinsically lower platelet counts and greater risk for bleeding in adults than children. PLoS Negl Trop Dis. 2012;6(6):1679. doi: 10.1371/journal.pntd.0001679
19. Salgado DM, Eltit JM, Mansfield K, Panqueba C, Castro D, Roció Vega R, et al. Heart and skeletal muscle are targets of dengue virus infection. Pediatr Infect Dis J. 2010;29 (3):238–242 doi: 10.1097/INF.0b013e3181bc3c5b
20. Sahu R, Verma R, Jain A, Garg R, Singh M, Malhotra H, et al. Neurologic complications in dengue virus infection: a prospective cohort study. Neurology. 2014;83 (18):1601–16 doi: 10.1212 / WNL.0000000000000935.
21. Carod-Artal FJ, Wichmann O, Farrar J, Gascón J. Neurological complications of dengue virus infection. Lancet Neurol. 2013;12(9):906–91948 doi: 10.1016 / S1474-4422 (13) 70150-9
22. Kuo MC, Lu PL, Chang JM, Lin MY,* Tsai JJ, Chen YH, et al. Impact of renal failure on the outcome of dengue viral infection. Clin J Am Soc Nephrol. 2008;3 (5):1350–1356 doi: 10.2215/CJN.00020108
23. Oliveira JF, Burdmann EA. Dengue-associated acute kidney injury. Clin Kidney J. 2015;8(6):681–685. doi: 10.1093/ckj/sfv106
24. Laoprasopwattana K, Pruekprasert P, Dissaneewate P, Geater A, Vachvanichsanong P. Outcome of dengue hemorrhagic fever-caused acute kidney injury in Thai children. J Pediatr. 2010;157(2):303–309. DOI: 10.1016 / j.jpeds.2010.02.008
25. Tan LH, Lum LC, Omar SF, Kan FK. Hemophagocytosis in dengue: comprehensive report of six cases. J Clin Virol. 2012;55(1):79– 82. doi: 10.1016 / j.jcv.2012.06.005
26. Thein TL, Ng EL, Yeang MS, Leo YS, Lye DC. Risk factors for concurrent bacteremia in adult patients with dengue. J Microbiol Immunol Infect. 2015. doi:10.1016/j.jmii.2015.06.008
27. Castro JE, Vado-Solis I, Perez-Osorio C, Fredeking. TM. Modulation of cytokine and cytokine receptor/antagonist by treatment with doxycycline and tetracycline in patients with dengue fever. Clin Dev Immunol. 2011; 2011:370872 doi: 10.1155 / 2011/370872
28. Global strategy for Dengue prevention and control 2012-2020.WHO Library 2012. ISBN 978 92 4 150403 4
La revista no retiene los derechos de reproducción (copyright) por lo que los autores pueden volver a publicar sus trabajos con la sola mención a la fuente original de publicación.